Ideal Power Inc
For the period ended Dec 31, 2023. Filed Apr 1, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 1, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 8. : FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
| ITEM 8: | FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
|---|
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
Ideal Power, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Ideal Power, Inc. (the “Company”) as of December 31, 2023 and 2022, and the related statements of operations, stockholders’ equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform an audit of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.
Critical Audit Matters
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.
Carrying Value of Intangible Assets
As described in Note 2 to the financial statements, the Company’s intangible asset, net balance was $2.6 million as of December 31, 2023. The Company capitalizes third-party legal costs and filing fees, if any, associated with obtaining patents or other intangible assets. Once the patent asset has been placed in service, the Company amortizes these costs over the shorter of the asset’s legal or estimated economic life using the straight-line method. The Company also evaluates for potential impairment of long-lived assets, including intangible assets composed of patents, no less frequently than annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.
The principal considerations for our determination that performing procedures relating to the carrying value of intangible assets is a critical audit matter are the significant amount of judgment by management in developing the assumptions of future economic benefit in an impairment analysis, which in turn led to significant auditor judgment, subjectivity and effort in performing audit procedures and evaluating audit evidence relating to the analysis.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements. These procedures included, among others, reviewing current and forecasted operating conditions for indication of impairment. We also reviewed board minutes, news, and industry reports for indications of impairment. Last, we obtained an understanding of potential future customers indicating future recoverability.
/s/BPM LLP
We have served as the Company’s auditor since 2013.
San Jose, California
April 1, 2024
Balance Sheets
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $8,474,835 | $16,345,623 |
| Accounts receivable, net | 70,000 | 65,936 |
| Inventory | 81,450 | — |
| Prepayments and other current assets | 482,890 | 491,365 |
| Total current assets | 9,109,175 | 16,902,924 |
| Property and equipment, net | 359,225 | 200,103 |
| Intangible assets, net | 2,580,066 | 2,036,431 |
| Right of use asset | 186,570 | 248,720 |
| Other assets | 13,034 | 11,189 |
| Total assets | $12,248,070 | $19,399,367 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $405,098 | $130,503 |
| Accrued expenses | 455,112 | 254,218 |
| Current portion of lease liability | 70,683 | 64,597 |
| Total current liabilities | 930,893 | 449,318 |
| Long-term lease liability | 132,304 | 202,987 |
| Other long-term liabilities | 1,125,173 | 838,458 |
| Total liabilities | 2,188,370 | 1,490,763 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2023 and 2022 | — | — |
| Common stock, $0.001 par value; 50,000,000 shares authorized; 5,998,018 shares issued and 5,996,697 shares outstanding at December 31, 2023 and 5,926,001 shares issued and 5,924,680 shares outstanding at December 31, 2022 | 5,998 | 5,926 |
| Additional paid-in capital | 107,116,362 | 105,011,318 |
| Treasury stock, at cost; 1,321 shares at December 31, 2023 and 2022, respectively | (13,210) | (13,210) |
| Accumulated deficit | (97,049,450) | (87,095,430) |
| Total stockholders’ equity | 10,059,700 | 17,908,604 |
| Total liabilities and stockholders’ equity | $12,248,070 | $19,399,367 |
Statements of Operations
| For the Year Ended | ||
|---|---|---|
| December 31, | ||
| 2023 | 2022 | |
| Commercial revenue | $161,483 | $— |
| Grant revenue | 37,388 | 203,269 |
| Total revenue | 198,871 | 203,269 |
| Cost of commercial revenue | 123,225 | — |
| Cost of grant revenue | 37,388 | 203,269 |
| Total cost of revenue | 160,613 | 203,269 |
| Gross profit | 38,258 | — |
| Operating expenses: | ||
| Research and development | 5,743,211 | 3,366,776 |
| General and administrative | 3,533,383 | 3,123,852 |
| Sales and marketing | 1,113,752 | 852,331 |
| Total operating expenses | 10,390,346 | 7,342,959 |
| Loss from operations | (10,352,088) | (7,342,959) |
| Interest income, net | 398,068 | 153,609 |
| Net loss | $(9,954,020) | $(7,189,350) |
| Net loss per share – basic and diluted | $(1.61) | $(1.17) |
| Weighted average number of shares outstanding – basic and diluted | 6,190,746 | 6,157,866 |
Statement of Stockholders’** Equity**
For the Years Ended December 31, 2023 and 2022
| Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Common Stock · Paid-In · Treasury Stock · Accumulated · Stockholders’ | |||||||
| Shares | Amount | Capital | Shares | Amount | Deficit | Equity | |
| Balances at December 31, 2021 | 5,893,767 | $5,894 | $104,063,321 | 1,321 | $(13,210) | $(79,906,080) | $24,149,925 |
| Exercise of options | 1,351 | 1 | (1) | — | — | — | — |
| Stock issued for services | 10,000 | 10 | 100,090 | — | — | — | 100,100 |
| Vesting of restricted stock units | 20,883 | 21 | (127,893) | — | — | — | (127,872) |
| Stock-based compensation | — | — | 975,801 | — | — | — | 975,801 |
| Net loss for the year ended December 31, 2022 | — | — | — | — | — | (7,189,350) | (7,189,350) |
| Balances at December 31, 2022 | 5,926,001 | 5,926 | 105,011,318 | 1,321 | (13,210) | (87,095,430) | 17,908,604 |
| Vesting of restricted stock units | 72,017 | 72 | (216,336) | — | — | — | (216,264) |
| Stock-based compensation | — | — | 2,321,380 | — | — | — | 2,321,380 |
| Net loss for the year ended December 31, 2023 | — | — | — | — | — | (9,954,020) | (9,954,020) |
| Balances at December 31, 2023 | 5,998,018 | $5,998 | $107,116,362 | 1,321 | $(13,210) | $(97,049,450) | $10,059,700 |
Statements of Cash Flows
| For the Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Cash flows from operating activities: | ||
| Net loss | $(9,954,020) | $(7,189,350) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 271,746 | 187,077 |
| Amortization of right of use asset | 62,150 | 58,452 |
| Write-off of long-lived assets | — | 937 |
| Stock-based compensation | 2,321,380 | 975,801 |
| Stock issued for services | — | 100,100 |
| Decrease (increase) in operating assets: | ||
| Accounts receivable | (4,064) | 167,326 |
| Inventory | (81,450) | — |
| Prepaid expenses and other assets | 6,630 | (447,465) |
| Increase (decrease) in operating liabilities: | ||
| Accounts payable | 274,595 | 3 |
| Accrued expenses and other liabilities | 36,052 | (177,931) |
| Lease liability | (64,597) | (58,864) |
| Net cash used in operating activities | (7,131,578) | (6,383,914) |
| Cash flows from investing activities: | ||
| Purchase of property and equipment | (240,825) | (182,651) |
| Acquisition of intangible assets | (282,121) | (130,089) |
| Net cash used in investing activities | (522,946) | (312,740) |
| Cash flows from financing activities: | ||
| Payment of taxes upon vesting of restricted stock units | (216,264) | (127,872) |
| Net cash used in financing activities | (216,264) | (127,872) |
| Net decrease in cash and cash equivalents | (7,870,788) | (6,824,526) |
| Cash and cash equivalents at beginning of year | 16,345,623 | 23,170,149 |
| Cash and cash equivalents at end of year | $8,474,835 | $16,345,623 |
Ideal Power Inc.
Notes to Financial Statements
Note 1 —Organization and Description of Business
Ideal Power Inc. (the “Company”) was incorporated in Texas on May 17, 2007 under the name Ideal Power Converters, Inc. The Company changed its name to Ideal Power Inc. on July 8, 2013 and re-incorporated in Delaware on July 15, 2013. With headquarters in Austin, Texas, the Company is focused on the further development and commercialization of its Bidirectional bipolar junction TRANsistor (B-TRAN™) solid-state switch technology.
Since its inception, the Company has financed its research and development efforts and operations primarily through the sale of common stock. The Company’s continued operations are dependent upon, among other things, its ability to obtain adequate sources of funding through future revenues, follow-on stock offerings, issuances of warrants, debt financing, co-development agreements, government grants, sale or licensing of developed intellectual property or other alternatives.
Note 2 —Summary of Significant Accounting Policies
Basis of Presentation
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Accounts Receivable
Trade accounts receivable are stated net of a provision for credit losses. The provision for credit losses represents an estimate of the lifetime expected credit losses inherent in trade receivables as of the balance sheet date. The Company assesses the adequacy of the provision for credit losses on a quarterly basis based on historical information and current economic conditions and forecasts. Subsequent changes in the provision for credit losses are recorded in current earnings and reversal of previous losses are permitted under the current guidance. While the Company believes it has exercised prudent judgment and applied reasonable assumptions, there can be no assurance that in the future, changes in economic conditions or other factors will not cause changes in the financial health of its customers. If the financial health of customers deteriorates, the timing and level of payments received could be impacted and therefore, could result in a change to the Company’s estimated losses.
Trade accounts receivable at December 31, 2023 relate to a product development agreement with Stellantis, a top 10 global automaker, for a custom B-TRAN™ power module for use in electric vehicle (“EV”) drivetrain inverters in Stellantis’ next generation EV platform. At December 31, 2023, the provision for credit losses was $0.
Property and Equipment
Property and equipment are stated at historical cost less accumulated depreciation and amortization. Major additions and improvements are capitalized while maintenance and repairs that do not improve or extend the useful life of the respective asset are expensed. Depreciation and amortization of property and equipment is computed using the straight-line method over their estimated useful lives. Leasehold improvements are amortized over the shorter of the life of the asset or the related leases. Estimated useful lives of the principal classes of assets are as follows:
| Leasehold improvements | Shorter of lease term or useful life (in years) | ||
|---|---|---|---|
| Machinery and equipment | 5 | ||
| Furniture, fixtures and IT equipment | 3 | – | 5 |
Intangible Assets
The Company’s intangible assets are composed of patents and trademarks, which are recorded at cost, and other intangible assets, which are recorded at cost plus the estimated present value of all future payments associated with the other intangible assets. The Company capitalizes third-party legal costs and filing fees, if any, associated with obtaining patents, trademarks or other intangible assets. Once the patent asset has been placed in service, the Company amortizes these costs over the shorter of the asset’s legal life, generally 20 years from the initial filing date, or its estimated economic life using the straight-line method. Trademarks are not amortized as trademarks have an indefinite useful life. For the other intangible assets, the Company amortizes the assets over the 11-year and 17‑year terms of the underlying agreements.
Impairment of Long-Lived Assets
The long-lived assets, consisting of property and equipment and intangible assets, held and used by the Company are reviewed for impairment no less frequently than annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In the event that facts and circumstances indicate that the cost of any long-lived assets may be impaired, an evaluation of recoverability is performed. Management has determined that there was an impairment in the value of long-lived assets in the amount of $937 during the year ended December 31, 2022. There wereno impairments in the value of long-lived assets during the year ended December 31, 2023.
Fair Value
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities measured at fair value are categorized based on whether or not the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The three levels of inputs used to establish fair value are the following:
| ● | Level 1 — Quoted prices in active markets for identical assets or liabilities; |
| ● | Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; and |
| ● | Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities |
The Company’s financial instruments primarily consist of cash and cash equivalents, accounts payable and long-term liabilities. As of the balance sheet dates, the estimated fair values of the financial instruments were not materially different from their carrying values as presented on the balance sheets. This is primarily attributed to the short-term nature of these instruments.
In 2015, the Company recorded a long-term liability for the estimated present value of future payments under licensing agreements. In 2021, the Company recorded an adjustment to increase the long-term liability due to an increase in the future payments due under these licensing agreements. In 2023, the Company recorded a long-term liability for the estimated present value of future payments under a separate licensing agreement. The Company determined the discount rate to estimate the present value of the future payments based on the applicable treasury rates. The Company’s long-term liability is classified within Level 3. See Note 5 and Note 8 for more details regarding the licensing agreements. The Company did not identify any other assets and liabilities that are required to be presented in the balance sheets at fair value.
Revenue Recognition
The Company recognizes revenue and related cost of revenue in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 606, “Revenue from Contracts with Customers” and, as applicable, with the guidance issued by the FASB in June 2018 for the recipients of grants.
In 2023, the Company recognized commercial revenue and grant revenue. Government contracts, including grants, are agreements that generally provide the Company with cost reimbursement for certain types of development activities over a contractually defined period. Grant revenue is recognized in the period during which the Company incurs the related costs, provided that the Company has incurred the cost in accordance with the specifications and work plans determined between the Company and the government entity. Commercial revenue relates to either the development agreements with customers or product sales. Commercial revenue under development agreements is generally recognized upon the completion of contractual deliverables. Commercial revenue from product sales is generally recognized upon shipment of products.
For the year ended December 31, 2023, the Company recognized $161,483 of commercial revenue and $37,388 of grant revenue. For the year ended December 31, 2022, the Company recognizedno commercial revenue and $203,269 of grant revenue. The Company did not have any active government contracts, including grants, at December 31, 2023.
Research and Development
Research and development costs are presented as a line item under operating expenses and are expensed as incurred. Research and development costs include costs to further develop the Company’s B-TRAN™ technology and related products and include, but are not limited to, the cost of engineering personnel, wafer fabrication, contract labor, driver design and fabrication, device packaging, product development, testing and other engineering services, stock-based compensation for engineering personnel, consulting and materials and supplies.
Income Taxes
The Company accounts for income taxes using an asset and liability approach which allows for the recognition and measurement of deferred tax assets based upon the likelihood of realization of tax benefits in future years. Under the asset and liability approach, deferred taxes are provided for the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. A valuation allowance is provided for deferred tax assets if it is more likely than not these items will either expire before the Company is able to realize their benefits, or that future deductibility is uncertain. At December 31, 2023 and 2022, the Company established a full reserve against all deferred tax assets.
Tax benefits from an uncertain tax position are recognized only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position are measured based on the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate resolution.
Net Loss Per Share
The Company applies FASB ASC 260, “Earnings per Share.” Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted-average number of common shares outstanding. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include additional common shares available upon exercise of equity awards and warrants using the treasury stock method. In periods with a net loss, no common share equivalents are included because their effect would be anti-dilutive.
In accordance with ASC 260, shares issuable for little or no cash consideration are considered outstanding common shares and included in the computation of basic earnings per share. As such, the Company includes pre-funded warrants to purchase shares of common stock in its computation of earnings per share. The pre-funded warrants were issued in November 2019 with an exercise price of $0.001. See Note 11.
At December 31, 2023 and 2022, potentially dilutive shares outstanding amounted to 1,597,898 and 1,598,034 shares, respectively, and exclude pre-funded warrants to purchase shares of common stock.
Stock Based Compensation
The Company applies FASB ASC 718, “Stock Compensation,” when recording stock-based compensation. Grants to non-employees are also accounted for under ASC 718. The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option valuation model. The fair value of each performance stock unit award is estimated on the date of grant using a Monte Carlo simulation.
The Company issues common stock upon exercise of equity awards and warrants.
Concentration of Credit Risk
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash with a major financial institution located in the United States. Balances are insured by the Federal Deposit Insurance Corporation up to $250,000. The Company maintains balances in excess of federally insured limits. The Company has not experienced losses in such accounts and believes it is not exposed to significant credit risk regarding its cash and cash equivalents.
Recent Accounting Pronouncements
Management does not believe that any recently issued, but not yet effective, accounting standards, if adopted, would have a material impact on the Company’s financial statements.
Note 3 —Prepayments and Other Current Assets
Prepayments and other current assets consisted of the following:
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Prepaid insurance | $204,572 | $213,357 |
| Prepaid semiconductor fabrication costs | 88,150 | 110,319 |
| Prepaid software | 64,082 | 71,141 |
| Prepaid inventory | 58,200 | — |
| Prepaid consulting | — | 32,000 |
| Prepaid engineering services | — | 26,000 |
| Other | 67,886 | 38,548 |
| $482,890 | $491,365 | |
Note 4 —Property and Equipment
Property and equipment, net consisted of the following:
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Machinery and equipment | $392,395 | $233,431 |
| Building leasehold improvements | 10,245 | 10,245 |
| Furniture, fixtures, software and IT equipment | 175,593 | 98,793 |
| 578,233 | 342,469 | |
| Accumulated depreciation and amortization | (219,008) | (142,366) |
| $359,225 | $200,103 | |
Depreciation expense amounted to $81,703 and $37,769 for the years ended December 31, 2023 and 2022, respectively. During the year ended December 31, 2023, the Company wrote-off $5,061 in fully depreciated property and equipment. During the year ended December 31, 2022, the Company wrote-off $937 in property and equipment.
Note 5 —Intangible Assets
Intangible assets, net consisted of the following:
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Patents | $1,530,257 | $1,263,930 |
| Trademarks | 15,794 | — |
| Other intangible assets | 1,843,036 | 1,391,479 |
| 3,389,087 | 2,655,409 | |
| Accumulated amortization - patents | (272,872) | (211,078) |
| Accumulated amortization – other intangible assets | (536,149) | (407,900) |
| $2,580,066 | $2,036,431 | |
At December 31, 2023 and 2022, the Company had capitalized $460,890 and $341,610, respectively, for costs related to patents that have not been awarded. Costs related to patents that have not been awarded are not amortized until patent issuance. As further discussed in Note 8, the Company entered into a license agreement in April 2023 and capitalized $451,557 in other intangible assets related to this agreement.
Amortization expense amounted to $190,043 and $149,308 for the years ended December 31, 2023 and 2022, respectively. Amortization expense for the succeeding five years and thereafter is $206,181 (2024‑2028) and $1,072,477 (thereafter).
Note 6 —Accrued Expenses
Accrued expenses consisted of the following:
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Accrued compensation | $185,494 | $70,261 |
| Accrued Board fees | 62,500 | 62,500 |
| Accrued professional fees | 79,156 | 53,300 |
| Accrued licensing fees | 100,000 | 50,000 |
| Accrued taxes | — | — |
| Other | 27,962 | 18,157 |
| $455,112 | $254,218 | |
Note 7—** Lease**
In March 2021, the Company entered into a lease agreement for 4,070 square feet of office and laboratory space located in Austin, Texas. The commencement of the lease occurred on June 1, 2021 and the initial term of the lease was 63 months. The actual base rent in the first year of the lease was $56,471 and was net of $18,824 in abated rent over the first three months of the lease term. The annual base rent in the second year of the lease is $77,330 and increases by $2,035 in each succeeding year of the lease. In addition, the Company is required to pay its proportionate share of operating costs for the building under this triple net lease. The lease contains a 5-year fair market renewal option. It does not contain a termination option. The Company recognized a right of use asset of $339,882 and a corresponding lease liability for this lease upon lease commencement.
For purposes of calculating the right of use asset and lease liability included in the Company’s financial statements, the Company estimated its incremental borrowing rate at 6% per annum.
Future minimum payments under the lease are as follows:
| For the Year Ended December 31, | |
|---|---|
| 2024 | $80,552 |
| 2025 | 82,587 |
| 2026 | 56,132 |
| Total lease payments | 219,271 |
| Less: imputed interest | (16,284) |
| Total lease liability | 202,987 |
| Less: current portion of lease liability | (70,683) |
| Long-term lease liability | $132,304 |
For the year ended December 31, 2023, operating cash outflows for lease payments totaled $78,517 and the operating lease cost, recognized on a straight-line basis, totaled $76,070. For the year ended December 31, 2022, operating cash outflows for lease payments totaled $76,482 and the operating lease cost, recognized on a straight-line basis, totaled $76,070. At December 31, 2023, the remaining lease term was 32 months.
Note 8—** Commitments and Contingencies**
Licensing Agreements
In 2015, the Company entered into a licensing agreement which expires in February 2033. Per the agreement, the Company has an exclusive royalty-free license associated with semiconductor power switches which enhances its intellectual property portfolio. The Company pays $100,000 annually under this agreement.
In 2023, the Company amended a 2021 license agreement which expires in February 2034. Per the agreement, the Company has an exclusive royalty-free license associated with semiconductor drive circuitry which enhances its intellectual property portfolio. The Company pays $50,000 annually under this agreement. At inception, the Company recorded an intangible asset and other long-term liability of $451,557 for the estimated present value of future payments under this licensing agreement.
The Company is accruing interest for future payments related to these agreements.
Legal Proceedings
The Company may be subject to litigation from time to time in the ordinary course of business. The Company is not currently party to any legal proceedings.
Indemnification Obligations
The employment agreements of Company executives include an indemnification provision whereby the Company shall indemnify and defend, at the Company’s expense, its executives so as long as an executive’s actions were taken in good faith and in furtherance of Company’s business and within the scope of executive’s duties and authority.
Note 9 —Equity
All shares of common stock have a par value of $0.001. Each holder of common stock is entitled toone vote per share outstanding.
Stock Issuances
In 2022, the Company issued 10,000 unregistered shares of common stock, valued at $100,100 at the time of issuance, to a third-party vendor as compensation for services performed.
Note 10 —** Equity Incentive Plan**
In May 2013, the Company adopted the 2013 Equity Incentive Plan (as amended and restated, the “Plan”) and reserved shares of common stock for issuance under the Plan, which was last amended in June 2023. The plan is administered by the Compensation Committee of the Company’s Board of Directors (the “Board”). At December 31, 2023, there were 504,549 shares of common stock available for issuance under the Plan.
During the year ended December 31, 2023, the Company granted 12,000 stock options to employees,27,550 restricted stock units to Board members and 60,200 restricted stock units to employees under the Plan. During the year ended December 31, 2023, the Company granted no awards to executives under the Plan. The estimated fair value of these equity grants, calculated using the Black-Scholes option valuation model for the stock options, was $915,789, of which $363,563 was recognized in the respective department expenses in the statement of operations for the year ended December 31, 2023.
During the year ended December 31, 2022, the Company granted 31,062 stock options to Board members,57,500 restricted stock units and 97,500 performance stock units to executives and 30,000 stock options,59,500 restricted stock units and 16,500 performance stock units to employees under the Plan. The estimated fair value of these equity grants, calculated using the Black-Scholes option valuation model for the stock options and a Monte Carlo simulation model for the performance stock units, which contain market conditions, was $2,688,111, of which $320,722 was recognized in the respective department expenses in the statement of operations for the year ended December 31, 2022.
As permitted by SAB 107, management utilizes the simplified approach to estimate the expected term of stock options, which represents the period of time that options granted are expected to be outstanding. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. treasury yield in effect at the time of grant. The volatility is estimated based on the historical volatilities of comparable companies. The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.
The assumptions used in the Black-Scholes model are as follows:
| For the year ended December 31, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| Average risk-free interest rate | 4.13% | 2.67% | ||
| Expected dividend yield | —% | — | ||
| Expected life (in years) | 6.00 | 5.25 | to | 6.00 |
| Expected volatility | 90% | 90% | ||
During the year ended December 31, 2022, the Company utilized the same expected volatility in both the Black-Scholes model for stock options and the Monte Carlo simulation for performance stock units.
A summary of the Company’s stock option activity and related information is as follows:
| 2023 · 2022 | ||||||
|---|---|---|---|---|---|---|
| Weighted · Weighted | ||||||
| Weighted · Average · Weighted · Average | ||||||
| Average · Remaining · Average · Remaining | ||||||
| Stock | Exercise | Life | Stock | Exercise | Life | |
| Options | Price | (in years) | Options | Price | (in years) | |
| Outstanding at January 1 | 513,948 | $7.59 | 6.6 | 492,886 | $7.35 | 7.6 |
| Granted | 12,000 | $11.96 | 61,062 | $11.09 | ||
| Exercised | — | $— | (3,750) | $5.36 | ||
| Forfeited / Expired | — | $— | (36,250) | $10.45 | ||
| Outstanding at December 31 | 525,948 | $7.69 | 5.7 | 513,948 | $7.59 | 6.6 |
| Exercisable at December 31 | 475,287 | $7.18 | 5.4 | 443,284 | $6.78 | 6.2 |
The following table sets forth additional information about stock options outstanding at December 31, 2023:
| Weighted | ||||||
|---|---|---|---|---|---|---|
| Average · Weighted | ||||||
| Remaining · Average | ||||||
| Options · Life · Exercise · Options | ||||||
| Range of Exercise Prices · Outstanding · (in years) · Price · Exercisable | ||||||
| $1.99 | – | $2.85 | 181,557 | 4.3 | $2.52 | 181,557 |
| $4.25 | – | $9.31 | 176,736 | 6.5 | $7.33 | 176,736 |
| $10.41 | – | $17.25 | 163,302 | 6.4 | $12.75 | 112,641 |
| $31.50 | – | $79.40 | 4,353 | 2.6 | $48.50 | 4,353 |
| 525,948 | 475,287 | |||||
Stock options granted under the Plan haveten-year terms and generally vest immediately or annually over athree-year vesting period except for option grants to independent directors that generally vest quarterly over aone-year vesting period.
The estimated aggregate pretax intrinsic value (the difference between the Company’s stock price on the last day of the year ended December 31, 2023 and the exercise prices, multiplied by the number of in-the-money options) is $1.1 million for both outstanding and vested options. This amount changes based on the fair value of the Company’s stock.
A summary of the Company’s restricted stock unit (“RSU”) and performance stock unit (“PSU”) activity is as follows:
| 2023 | 2022 | |||
|---|---|---|---|---|
| RSUs | PSUs | RSUs | PSUs | |
| Outstanding at January 1 | 183,666 | 114,000 | 100,000 | — |
| Granted | 87,750 | — | 117,000 | 114,000 |
| Vested | (99,886) | — | (33,334) | — |
| Outstanding at December 31 | 171,530 | 114,000 | 183,666 | 114,000 |
In the year ended December 31, 2023,99,886 restricted stock units vested of which 27,869 restricted stock units were forfeited to cover employee and executive payroll tax withholding obligations. In the year ended December 31, 2022,33,334 restricted stock units vested of which 12,451 restricted stock units were forfeited to cover the executives’ payroll tax withholding obligations. The payment of the taxes on the vesting of the restricted stock units is shown as a financing activity on the statement of cash flow.
As of December 31, 2023, there was $1,868,240 of unrecognized compensation cost related to non-vested share-based compensation arrangements. That cost is expected to be recognized over a weighted average period of 1.0 years.
Note 11 —Warrants
At December 31, 2023 and 2022, there were 786,420 warrants outstanding at a weighted average exercise price of $5.19 and 253,828 pre-funded warrants outstanding at a weighted average exercise price of $0.001.
All warrants were exercisable at December 31, 2023 although warrants may generally be exercised only to the extent that the total number of shares of common stock then beneficially owned by these shareholders does not exceed 4.99% (or, at the investor’s election,9.99%) of the outstanding shares of the Company’s stock.
The weighted average remaining life, excluding the 253,828 pre-funded warrants with no expiration date, of the outstanding warrants is 1.2 years.
The estimated aggregate pre-tax intrinsic value (the difference between the Company’s stock price on the last day of the year ended December 31, 2023 and the exercise prices, multiplied by the number of in-the-money warrants) is $4.4 million.
Note 12 —Income Taxes
Income taxes are disproportionate to income due to net operating loss carryforwards, which are fully reserved. As of December 31, 2023, the Company has federal net operating loss carryforwards of approximately $70 million. The federal net operating loss carryforward for years prior to 2018 expire from 2031 through 2038. Federal net operating loss carryforwards for year 2018 and thereafter do not expire.
Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carryforwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had one or more changes in control under these Sections. However, the Company does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carryforwards until the time that it projects it will be able to utilize these tax attributes.
Management has concluded that it is more likely than not that the Company will not have sufficient foreseeable taxable income within the carryforward period as applicable and permitted by current law to allow for the utilization of certain of the deductible amounts generating the deferred tax assets; therefore, a full valuation allowance has been established to reduce the net deferred tax assets tozero at December 31, 2023 and 2022.
The following is a summary of the significant components of the Company’s net deferred income tax assets and liabilities as of December 31, 2023 and 2022:
| For the Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Current deferred income tax assets: | ||
| Accrued compensation and other | $31,000 | $11,000 |
| Less: valuation allowance | (31,000) | (11,000) |
| $— | $— | |
| Non-current deferred income tax assets and (liabilities): | ||
| Net operating loss | $14,686,000 | $13,642,000 |
| Research and development credit | 18,000 | 18,000 |
| Research and experimental costs | 1,207,000 | 595,000 |
| Warrants issued for services | 45,000 | 45,000 |
| Depreciation and amortization | 227,000 | 135,000 |
| Exercise of options and warrants | (36,000) | (36,000) |
| Stock based compensation | 1,718,000 | 1,149,000 |
| Intangibles and other | (787,000) | (633,000) |
| Less: valuation allowance | (17,078,000) | (14,915,000) |
| Net non-current deferred tax assets | $— | $— |
The Company has applied the provisions of FASB ASC 740,Income Tax, which clarifies the accounting for uncertainty in tax positions. FASB ASC 740 requires the recognition of the impact of a tax position in the financial statements if that position is more likely than not of being sustained on a tax return upon examination by the relevant taxing authority, based on the technical merits of the position. At December 31, 2023 and 2022, the Company hadno unrecognized tax benefits.
The Company recognizes interest and penalties related to income tax matters in interest expense and operating expenses, respectively. As of December 31, 2023 and 2022, the Company hasno accrued interest and penalties related to uncertain tax positions.
The Company is subject to tax in the United States (“U.S.”) and files tax returns in the U.S. federal and certain state jurisdictions. The Company is generally no longer subject to U.S. federal, state and local income tax examinations by tax authorities for all tax years since inception due to the carryover of unused net operating losses and tax credits. The Company currently is not under examination by any tax authority.
The reconciliation between the statutory income tax rate and the effective tax rate is as follows:
| For the Year Ended | ||
|---|---|---|
| December 31, | ||
| 2023 | 2022 | |
| Statutory federal income tax rate | (21)% | (21)% |
| Valuation allowance | 21 | 21 |
| —% | —% | |
Note 13 —Subsequent Event
In March 2024, the Company issued and sold 1,366,668 shares of its common stock at a price of $7.50 per share and 633,332 pre-funded warrants to purchase shares of common stock at a price of $7.499 per pre-funded warrant in an underwritten public offering (the “March 2024 Offering”). The pre-funded warrants have an exercise price of $0.001 per share. The underwriter has a 30-day option to purchase up to an additional 300,000 shares of common stock at the offering price, less the underwriting discounts and commissions. The estimated net proceeds to the Company from the March 2024 Offering are $13.6 million as of April 1, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.